←Back to list

BigHat Biosciences

Clinical-stage AI protein-therapeutics company pairing ML design with an autonomous wet-lab data platform
BigHat Biosciences, founded in 2019 by Mark DePristo (ex-Google AI genomics head) and Peyton Greenside (now CEO), designs protein therapeutics by combining machine learning with an autonomous wet-lab platform that generates proprietary biological data at scale. The San Mateo company is clinical-stage: BHB810 is described as one of the first AI-designed biologics to reach the clinic, and BHB299 is also in its pipeline. On 2026-09-24 it announced a $75M Series C co-led by DFJ Growth and Premji Invest, with a16z, Section 32, Amgen Ventures, Eli Lilly and Merck GHIF among returning investors, bringing total funding to $223M. Earlier it raised a $19M Series A (2021) and a $75M Series B led by Section 32 (2022). No valuation has been disclosed.
Drug Discovery 📍 San Mateo, CA Founded 2019
Current Valuation
Private
PRIVATE

IPO Outlookprivate

Is BigHat Biosciences going public?
No. BigHat Biosciences is private and has not filed to go public. There is no S-1 on file.
What is BigHat Biosciences' valuation in 2026?
No confirmed valuation is on record for BigHat Biosciences. The roster shows funding and investors where they are public; it does not estimate a mark.
Has BigHat Biosciences filed an S-1?
No public S-1 is on file for BigHat Biosciences.
Who are BigHat Biosciences' investors?
BigHat Biosciences' investors include DFJ Growth, Premji Invest, Section 32, Andreessen Horowitz, 8VC, Amgen Ventures and 10 more.
How much has BigHat Biosciences raised?
BigHat Biosciences has raised $223M in total across 3 disclosed rounds, most recently a Series C of $75M in Sep 2026.
Is BigHat Biosciences publicly traded — can you buy BigHat Biosciences stock?
No. BigHat Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for BigHat Biosciences on its Pre-IPO Access Desk.
How to actually get exposure to BigHat Biosciences →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

CEO
Peyton Greenside
Founded
2019
HQ
San Mateo, CA
Total Raised
$223M
Last Round
Series C — $75M (Sep 2026) · Lead: DFJ Growth; Premji Invest (co-leads)
IPO Status
private

Fundraising Status

Series C · $75M · 2 mo ago
privateTotal raised $223M3 disclosed rounds

Growth & Valuation

Capital raised per round
Capital raised per funding round$19MSeries A$75MSeries B$75MSeries C
Charts built from publicly disclosed funding rounds and revenue estimates. Approximate, not real-time, not investment advice.

Funding History

RoundAmountDateLead InvestorPost-Money
Series C$75MSep 2026DFJ Growth; Premji Invest (co-leads)—
Series B$75MJul 2022Section 32—
Series A$19MFeb 2021——

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Gastric Cancer
Gastric Adenocarcinoma · Gastric (Stomach) Cancer
Latest trial start
2026-07-16
Name-verified against lead sponsor "BigHat Biosciences, Inc." on ClinicalTrials.gov as of 2026-11-04. Verify on ClinicalTrials.gov ↗

Talent Signal

Hiring trend
▶ Hiring steady
+3% vs 2026-09
Open roles
41
via careers page
Product-build share
80%
engineering, research, product, design
Trajectory
steady
heavy product build — 80% of open roles are product-building functions (engineering/research/product) — 23 of 41 open roles are research.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by month40Sep '2641Oct '26
Open roles by function
Open roles by functionResearch23Ops & People8Clinical & Science6Data & ML2Engineering2
■ product-building   ■ go-to-market / G&A
BigHat scientists talking in the labBigHat scientist pipetting samples at a lab benchBigHat-branded robotic arm in the automated labBigHat scientist working at a laptop beside lab automation equipmentBigHat scientist using a multichannel pipette at the benchScientist at a Hamilton STAR liquid-handling system in the BigHat lab
Counted from BigHat Biosciences's live job board as of 2026-10-27; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Mark DePristoPeyton Greenside

Investors

DFJ Growth · Premji Invest · Section 32 · Andreessen Horowitz · 8VC · Amgen Ventures · Eli Lilly and Company · Merck Global Health Innovation Fund · Alexandria Venture Investments · Quadrille Capital · GRIDS Capital · Discovery Ventures · Intermountain Ventures · Catalio Capital Management · LG Technology Ventures · Sigmas Group

Products

  • BHB810 (clinical-stage)
  • BHB299
  • Milliner AI/ML wet-lab platform
BiotechAI Drug DiscoveryAntibodiesProtein DesignClinical Stage
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.